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Abstract
Inhibitory synapses dampen neuronal activity through postsynaptic hyperpolarization. The 
composition of the inhibitory postsynapse and the mechanistic basis of its regulation, however, 
remains poorly understood. We used an in vivo chemico-genetic proximity-labeling approach to 
discover inhibitory postsynaptic proteins. Quantitative mass spectrometry not only recapitulated 
known inhibitory postsynaptic proteins, but also revealed a large network of new proteins, many of 
which are either implicated in neurodevelopmental disorders or are of unknown function. 
CRISPR-depletion of one of these previously uncharacterized proteins, InSyn1, led to decreased 
postsynaptic inhibitory sites, reduced frequency of miniature inhibitory currents, and increased 
excitability in the hippocampus. Our findings uncover a rich and functionally diverse assemblage 
of previously unknown proteins that regulate postsynaptic inhibition and might contribute to 
developmental brain disorders.
Introduction
Two anatomically distinct classes of synapses are present in the central nervous system: 
excitatory synapses, predominantly localized to postsynaptic spines; and inhibitory 
synapses, in which the postsynapse is typically embedded in the soma and dendritic shaft(1). 
Purification and analysis of the protein complexes of the excitatory postsynapse have led to 
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fundamental insights in neurobiology. These insights include how receptor trafficking, 
synaptic adhesion, cytoskeletal remodeling, and protein phosphorylation contribute to the 
synaptic plasticity underlying learning and memory(2, 3). Moreover, genetic perturbations of 
excitatory postsynaptic proteins are strongly implicated in developmental brain disorders 
and psychiatric conditions(4, 5).
In contrast, the biochemical purification and analysis of the inhibitory postsynaptic density 
(iPSD) has remained largely intractable. Accordingly, the molecular basis of postsynaptic 
inhibitory synapse regulation and its contribution to neurodevelopmental disorders is poorly 
understood. Recently, an affinity purification approach, BioID, has been developed that 
utilizes a promiscuous E.coli biotinylation enzyme BirAR118G (here termed BirA) fused to a 
bait protein expressed in cells(6). BirA-dependent covalent biotinylation occurs within 10–
50 nm of the bait protein and allows for efficient isolation and analysis of proximal proteins 
by streptavidin-based affinity purification and mass spectrometry(7). Compared to affinity 
purification methods, the BioID reaction is executed in situ, thus enabling the capture of 
protein complexes, including transient interactions and insoluble proteins from subcellular 
compartments refractory to biochemical isolation(8).
We adapted the BioID approach to enable in vivo BioID (iBioID) of synaptic complexes in 
mouse brain. We virally expressed inhibitory or excitatory PSD proteins fused to BirA to 
capture and purify their associated proteins. The method labels the corresponding 
postsynaptic structures in vivo, and enabled the identification of virtually all of the known 
proteins of the iPSD. It also revealed a large number of previously unknown proteins, 
including a rich diversity of transmembrane and signaling proteins. These results provide a 
molecular prospectus for the deeper understanding of synaptic physiology that was until now 
largely confined to the excitatory PSD.
In Vivo Capture of Synaptic Protein Complexes
Gephyrin is the major scaffolding protein organizing the iPSD structure, interacting directly 
with GlyRs or GABAARs and other molecules such as neuroligin-2 (NL2) and collybistin 
(Arhgef9)(9–11). To label proteins associated with synaptic proteins in the context of native 
tissue in vivo, we created Adeno-associated viral (AAV) constructs for the expression of 
gephyrin- and PSD-95-fused BirA, targeting the proteomes of inhibitory and excitatory 
postsynapses, respectively (Fig. 1A). To control for synapse specificity of biotinylation we 
also expressed soluble BirA, which non-specifically biotinylates proteins throughout the 
neuron. Each construct was validated by immunocytochemistry to determine its localization 
and synaptic site of biotinylation (Fig. 1B). To label synaptic structures in vivo we 
developed a protocol that maximizes the number of synapses labeled by injection of AAV 
into the cortex of postnatal day 0 (P0) mouse pups, followed by seven days of daily doses of 
exogenous biotin (Fig. 1C). Immunohistochemical analysis validates the approach for in 
vivo biotinylation (Fig. 1D), yielding punctate labeling of synaptic sites in brain tissue (Fig. 
1E). Immuno-electron microscopy verified that biotinylation occurred at symmetric (i.e. 
inhibitory) synapses for BirA-gephyrin, and at asymmetric (i.e. excitatory) postsynaptic sites 
for PSD-95-BirA (Fig. 1F, G). Subcellular sites of background staining (perhaps due to 
overexpression or detection of endogenous biotinylated carboxylases) were also noted to 
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guide the final proteomic analysis (Fig. S1A and Table S1). Purification of biotinylated 
proteins from neurons expressing each BirA fusion protein and subsequent immunoblotting 
for known components of inhibitory (collybistin) and excitatory (NR2B and GluA1) 
synapses verified that each bait specifically labeled components of these synaptic sites, 
versus the non-specific labeling of our negative control, soluble BirA (Fig. 1H).
Discovery of the Inhibitory Postsynaptic Proteome
To pilot the identification of proteins labeled by iBioID, four cohorts were prepared each for 
BirA, PSD-95-BirA, and BirA-gephyrin using the labeling protocol outlined in Fig. 1C. 
Biotinylated proteins purified by streptavidin affinity purification were identified by liquid 
chromatography tandem mass spectrometry (LC/MS/MS). In total, 928 unique proteins were 
identified from twelve separate LC/MS/MS runs, with unique compliments of proteins 
enriched over BirA in each synaptic fraction (Fig. S1B–E, Table S2). Analysis of the 
gephyrin-BirA fraction confirmed several proteins reported to reside at the iPSD(10, 12), 
including Arhgef9/collybistin, VASP family proteins Mena and Evl, and IQSEC3, and two 
proteins of unknown function, which we termed “inhibitory synaptic proteins 1 and 2” or 
InSyn1 (UPF0583 protein C15orf59 homolog) and InSyn2 (Protein Fam196a). This pilot 
study suggested that while the BirA-gephyrin is highly specific, increased coverage of the 
iPSD would be desirable. We therefore expanded the analysis of the iPSD by performing the 
MS/MS analysis using more sensitive instrumentation, and by including additional BirA-
fusion proteins to further label the iPSD (collybistin-BirA and InSyn1-BirA) (Fig. S1, F and 
G). InSyn1 was included since functional studies (described below) verified it was an 
important component of the iPSD. Quantitative high-resolution LC/MS/MS was then 
performed for each sample (PSD dataset: BirA versus PSD-95; iPSD dataset: BirA versus 
gephryin, collybistin, InSyn1) in biological triplicates (7–8 mice per biological fraction). For 
the excitatory PSD-95 dataset 18,207 peptides corresponding to 2,533 unique proteins were 
quantified, whereas 17,024 peptides corresponding to 2,183 proteins were quantified from 
the iPSD datasets. Proteins were considered significantly enriched in the bait fraction if their 
average BirA-fusion protein levels were at least 2-fold greater than the BirA-alone fractions 
with p-values <0.05. Based on these criteria, 121 ePSD proteins (Fig. S2) were specifically 
labeled by PSD-95-BirA (Table S3). More than 95% of the ePSD proteins identified by 
iBioID were previously known ePSD components as identified by traditional PSD 
biochemical fractionation and mass spectrometry (116 of 121 proteins), demonstrating the 
specificity of the method. These proteins included glutamate receptors, scaffolding proteins, 
and signaling proteins of excitatory synaptic complexes. The iPSD dataset identified a 
combined 181 proteins (Table S4), including nearly all previously reported proteins of the 
iPSD (13), suggesting that coverage of the iPSD had approached saturation (Fig. 2). We also 
identified a large number of proteins not previously known to reside at the iPSD, including 
trafficking proteins, cytoskeletal regulatory proteins, integral membrane proteins, and several 
protein kinases and phosphatases (Fig. 2B). Many of these proteins (27/181) are encoded by 
genes implicated in either seizure susceptibility in humans or mice, or other brain disorders 
such as intellectual disability (ID) (Table S4). Comparison of iPSD and PSD95 identified 17 
proteins shared by the two datasets, 50% of which are signaling proteins (Table S5).
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Candidate iPSD proteins co-localize and co-immunoprecipitate with 
gephyrin
To validate our iBioID results, select iPSD proteins (InSyn1, InSyn2, IQSEC3, Collybistin 
[Arhgeg9], and PX-RICS [Arhgap32]) were cloned and co-expressed in primary neuronal 
cells with GPHN.FingR-GFP, a marker of endogenous gephyrin(14) (Fig. 3A). Collybistin 
served as a positive control, while PSD-95 co-localization served as negative control. 
Quantification of co-localizing pixels (Fig. 3B) demonstrated that each iPSD protein 
significantly overlapped with endogenous gephyrin. Each candidate protein was also tested 
in co-immunoprecipitation experiments. Epitope-tagged iPSD proteins specifically co-
precipitated with GFP-gephyrin, including InSyn1 and InSyn2 (Fig. 3C–F).
InSyn1 and InSyn2 are iPSD proteins functionally important for GABAergic 
inhibition
InSyn1 is a previously uncharacterized protein that lacks protein domains of known 
function, but whose extensive iBioID interactions with core components of the iPSD 
(gephyrin, neuroligin-2, collybistin, GABAAR subunit beta-3), suggested a central role in 
GABAAR-dependent synaptic inhibition. To test if InSyn1 is functionally important for 
synaptic inhibition, we used single-cell CRISPR-mediated depletion of the endogenous 
protein (15) (Fig. 4A). GABAAR-mediated miniature inhibitory postsynaptic currents 
(mIPSCs) were recorded from CA1 pyramidal cells in hippocampal slices that were 
biolistically transfected with GFP, spCas9, and validated InSyn1 gRNA (Fig. 4B). 
Untransfected (GFP-negative) cells located within a 400 μm radius from GFP-positive cells 
served as controls, and gRNA specificity was tested by re-expression of Cas9-resistant 
cDNAs (Fig. 4B). Inhibitory currents were confirmed to be GABAergic because they were 
reversibly abolished in the presence of bicuculline (1 μM, Fig. S3A). To verify the efficacy 
of the CRISPR strategy for functional testing of iPSD synaptic proteins, we targeted the 
obligatory γ2 subunit of the GABAAR, finding a complete abolition of mIPSCs (Fig. S3B). 
We also verified that biolistic transfection of GFP alone did not alter mIPSC characteristics 
(Fig. S3,C–E). Using sgRNA targeting InSyn1 with and without an InSyn1 rescue construct, 
we found a significant and reversible 69% increase in mIPSC inter-event intervals (IEI); the 
difference in amplitude was not statistically significant (Fig. 4C–D). The effect of InSyn1 
gRNA was specific to inhibitory currents, as AMPAR-mediated mEPSC characteristics were 
unaltered (Fig. 5E–F). To further test the predictive value of the iPSD dataset, we performed 
analogous experiments targeting InSyn2. Depletion of InSyn2 resulted in a specific and 
reversible 62% increase of mIPSC IEI (Fig. S4).
Given the large effect of InSyn1 depletion on mIPSC frequency, we next asked whether the 
inhibitory deficits evident at the single-cell level manifest at the network level. We used a 
carbachol-induced model of the “awake-state” gamma rhythm, which is critically dependent 
on GABAergic inhibition(16). P0 Rosa26-LSL-Cas9(17) pups were bilaterally infused with 
AAV:Cre/InSyn1:gRNA virus or AAV:Cre/(-):gRNA control virus in the cortex and 
hippocampus (Fig. 4G). In the majority of acute slices prepared from control mice, 
carbachol (CCH) induced a pure gamma rhythm with peak frequencies of ~30–40 Hz (Fig. 
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4H, top trace). In contrast, the majority of InSyn1 gRNA-infected slices exhibited a mixture 
of gamma oscillations with hyperexcitable events including interictal epileptiform 
discharges (IEDs, Fig. 4H, middle trace) and prolonged (2–5 s) bursts resembling ictal 
discharges (Fig. 4H, lower trace). Overall, we found a 4-fold increase in the proportion of 
slices with IEDs (Fig. 4I). Power spectral analysis revealed a 2.2-fold increase in low-
frequency (0–15 Hz) power corresponding to epileptiform activity, and a 42% reduction in 
gamma-band (20–50 Hz) power (Fig. 4J). These effects likely reflect loss of GABAergic 
inhibition, as bath application of low concentrations of bicuculline (0.5 μM steps) abolished 
the gamma rhythm in control slices and induced epileptiform activity similar to that seen in 
InSyn1 gRNA slices (Fig. S3F).
InSyn1 functions via the dystrophin complex at inhibitory synaptic sites
We next analyzed how InSyn1 functions at inhibitory synapses by further examining its 
interacting proteins and how its loss alters the iPSD. InSyn1-GFP expressed in hippocampal 
neurons co-localized with gephyrin in dendritic shafts (Fig. S5A). InSyn1-GFP or GFP 
alone was expressed in the frontal cortex and hippocampus of C57BL/6 mice using AAV 
and precipitated using GFP-trap resin. InSyn1-GFP and GFP-alone co-precipitating proteins 
were analyzed by LC/MS/MS and compared. InSyn1 pulldown fractions were enriched with 
86 proteins (Fig. 5A. Table S6), forming a highly interconnected protein-protein interaction 
network that included many proteins in the iBioID iPSD (including InSyn2, gephyrin, and 
Iqsec3) (Fig. 5B).
Among the most enriched proteins were seven components of the dystrophin complex, 
including dystrophin (DMD), dystrobrevin alpha and beta (Dtna and Dtnb), and alpha-1, 
beta-1, and beta-2-syntrophins (Snta1, Sntb1, Sntb2) (Fig. 5C). In brain, the dystrophin 
complex is a component of the iPSD, and its loss in muscular dystrophies contributes to 
cognitive impairments and epilepsy(18). InSyn1-BirA also captured multiple components of 
the dystrophin complex (Fig. 2A–B), suggesting it forms a physical complex with both 
gephyrin and the dystrophin complex. Affinity purified anti-InSyn1 antibody recognized a 
band of approximately 50–52 kDa from cells transfected with HA-InSyn1 or from mouse 
brain extract (Fig. S5B). Immunofluorescence demonstrated that InSyn1 co-localizes with 
endogenous alpha-dystroglycan (α-DG); this punctate staining was lost in neurons cultured 
from Rosa26-LSL-Cas9 mice and infected with AAV:Cre/InSyn1:gRNA virus (Fig. 5D). 
Quantitative analysis demonstrated that InSyn1 gRNA-infected neurons had significant 
reductions in densities of both α-DG and GABAAR puncta and a significant a reduction in 
their co-localization (Fig. 5E–H). In contrast, the density of PSD-95 puncta was unaffected 
(Fig. 5I). These results are consistent with the reduced mIPSC frequencies we observed in 
single neuron CRISPR-mediated InSyn1 depletion, supporting the notion that the loss of 
postsynaptic sites of inhibition occurs in its absence.
Discussion
We report here the in vivo application of the BioID approach to analyze the local proteome 
of the postsynaptic compartment of inhibitory synapses by quantitative mass spectrometry. 
Comparing this approach to prior reports of the iPSD using affinity purification(19–21), 
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iBioID offers important advantages. Nearly all proteins previously reported to exist at the 
iPSD were identified. iBioID also identified 140 proteins not previously associated with the 
iPSD, including a wide range of signaling, transmembrane, structural, and uncharacterized 
proteins. Although we included multiple controls (BirA alone, EM analysis of nonspecific 
label) for the overexpression strategy, we anticipate future studies with endogenous proteins 
fused to BirA will likely further refine the iBioID approach.
To validate our results and to determine how the iPSD is regulated, we focused on two 
proteins of unknown function, InSyn1 and InSyn2, that associate with several core 
components of the iPSD. When expressed in neurons, both co-localized with endogenous 
gephyrin and their loss resulted in a significant reduction in mIPSC frequency, confirming 
the validity of the iBioID approach. The mechanism of reduced mIPSC frequency for 
InSyn1 is likely through the disruption of the ability of InSyn1 to form complexes with both 
gephyrin and the dystrophin complex at the iPSD. Loss of dystrophin might also lead to a 
secondary trans-synaptic effect on presynaptic release probability through its ability to bind 
neurexins(22, 23).
Twenty-seven of the proteins of the iPSD, including several proteins first identified here, are 
implicated by either human or mouse genetics in seizure susceptibility/familial epilepsy, ID, 
or autism (Fig. 2G). Of the newly identified iPSD proteins implicated in developmental 
disorders, many are signaling proteins or are proteins of unknown functions (Supplemental 
Discussion). It is also interesting to note that 17 proteins overlapped between the inhibitory 
and excitatory PSD fractions. These could reflect dual synapses (spines containing 
gephyrin(24)) or might represent signaling proteins that transit between synapse types to 
facilitate synaptic crosstalk.
Our results indicate the composition of the iPSD is far more complex than previously 
appreciated. This concept is in line both with emerging evidence of inhibitory synaptic 
plasticity at the postsynaptic specialization(25–32), and with our molecular evidence that the 
iPSD is associated with a variety of signaling proteins, analogous to that of excitatory 
synapses. The identification of the iPSD proteome provides a rational basis for investigating 
fundamental mechanisms that regulate synaptic inhibition. It also establishes a new 
reference frame to ascertain how perturbations of this protein complex may contribute to 
developmental brain disorders.
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Fig. 1. Development of iBioID for synaptic proteomics
(A) Schematic of the iBioID approach for synapses. (B) Validation of BirA constructs in 
hippocampal slice using (i) BirA-gephyrin and (ii) PSD-95-BirA (white arrows point to 
colocalized puncta). (iii) BirA alone non-specifically labels proteins. Scale bar, 2 μm. (C) 
Outline of iBioID method in mice. (D) Successful biotinylation of proteins in vivo following 
i.p. biotin administration. Scale bar, 0.5 mm (E) Biotinylation is specific to regions 
expressing BirA-gephyrin (coronal section). Insets from thalamus (e1) and hippocampus 
(e2) and insets of e2 are shown. Scale bar top panel, 0.5 mm; e1 and e2, 20 μm. Electron 
micrographs verify enrichment of biotinylation at (F, f′) inhibitory or (G, g′) excitatory PSD 
substructures. Large gold beads, streptavidin labeling; small gold beads, immunolabel for 
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GABA. Scale bar, 250 nm. (H) Specific purification of known PSD proteins for each BirA 
fusion protein.
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Fig. 2. Scale-free graph of the iPSD proteome
(A) InSyn1 (blue), gephyrin (green), and arhgef9 (yellow) BirA-dependent iBioID identifies 
a rich network of known and previously unknown proteins enriched at the iPSD. Node titles 
correspond to gene name; size represents fold-enrichment over negative control. Edges are 
shaded according to the types of interactions (grey, iBioID; black, protein-protein 
interactions previously reported). (B) Clustergram topology of iPSD proteins (red) in 
selected functional categories.
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Fig. 3. Validation of selected iPSD proteins
(A) Co-localization of iPSD proteins (left column) with endogenous gephyrin (right column) 
in hippocampal neurons. Scale bar, 10 μm. (B) Each iPSD protein significantly co-localizes 
with gephyrin in dendrites compared to PSD95 (n > 9 dendritic ROIs). (C–F) iPSD proteins 
co-immunoprecipitate with gephyrin when co-expressed in HEK293 cells. ***p<0.001 one-
way ANOVA followed by Dunnett’s multiple comparisons test (B). Error bars ± SEM.
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Fig. 4. Abnormal synaptic inhibition follows loss of the iPSD protein InSyn1
(A) Experimental schematic for panels C–F. (B) Validation of InSyn1 gRNAs (#12 & #17) 
and rescue constructs by 293T co-transfection and immunoblotting. (C, D) GABAA-
dependent miniature inhibitory postsynaptic currents (GABAA mIPSCs) recorded from CA1 
pyramidal cells. Inset shows GABAA mIPSC waveform averages. InSyn1 depletion did not 
alter mIPSC kinetics (rise: control = 3.6 ± 0.6 ms, InSyn1 = 3.4 ± 0.6 ms, p = 0.51; decay: 
control = 9.7 ± 2.1 ms, InSyn1 = 10.3 ± 1.8 ms, p = 0.42). IEIs of InSyn1-depleted GABAA 
mIPSCs (red) are specifically increased compared to control (black) and rescue (blue) 
neurons. (E, F) AMPAR-dependent miniature EPSCs are not altered in InSyn1 depleted 
neurons. (G) Time-line schematic for local field potential (LFP) recordings in acute slices 
from Cas9 knock-in (KI) mice infected with AAV:Cre/Insyn1 gRNA. Image shows 
representative extent of AAV infection in hippocampus. (H) Representative LFP activities 
recorded in hippocampal area CA3 in the presence of 10 μM carbachol to model “awake 
state” gamma rhythm. Top trace: pure 30–40 Hz gamma oscillation; middle trace: 3–5 Hz 
spike-wave discharges; bottom trace: ictal-like burst – the latter two indicative of 
hyperexcitable or epileptiform activity. (I) InSyn1 gRNA expressing slices exhibit increased 
epileptiform activity. (J) Averaged power spectra showing signal energy in the InSyn1 
gRNA expressing slices is increased in the 0–15 Hz frequency band and decreased in the 
20–50 Hz frequency bands. *p<0.05, **p<0.01, ***p<0.001, n.s. = not statistically 
significant. Error bars ±SEM.
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Fig. 5. InSyn1 functionally associates with the dystrophin complex at the iPSD
(A) Network analysis of affinity purified InSyn1-GFP proteome from mouse brain. (B, C) 
Clustergram topologies of InSyn1 associated proteins in selected functional categories. (D) 
Co-localization of InSyn1 with α-dystroglycan (α-DG) is diminished after depleting InSyn1 
with Cas9 conditional knock-in hippocampal neurons infected with AAV:Cre/Insyn1 gRNA. 
Scale bar, 10 μm. (E) InSyn1 is essential for GABAAR and α-DG cluster density. Cas9 KI 
hippocampal neurons were stained for GABAARγ2 and α-DG following infection with 
control AAV:Cre/(-)gRNA (top panel, Control); AAV:Cre/Insyn1 gRNA (middle panel, 
Knockdown), or AAV:Cre/Insyn1 gRNA, and transfected with InSyn1 gRNA resistant 
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plasmid (bottom panels, Rescue). Insets show higher magnification regions with open 
(colocalized puncta) and closed (non-colocalized puncta) arrows. (F, H) Quantification of α-
DG and GABAARγ2 puncta co-localization or density (n=16–18). *p<0.05, **p<0.01, 
***p<0.001 one-way ANOVA followed by Tukey’s multiple comparisons test (F–H). Error 
bars ± SEM. Scale bar, 10 μm. (I) Loss of InSyn1 does not alter PSD-95 puncta density. 
Cas9 knock-in hippocampal neurons infected with AAV:Cre/Insyn1 gRNA were stained with 
PSD-95 and quantified (n = 18–20 neurons). n.s = not significant, two-tailed t-test (I).
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